CRH Public Limited Co. - Form 8-K Summary
Business Context and Reporting Period
Company: CRH Public Limited Co.
Filing Date: June 21, 2026
Reporting Period: Current Report (Event Date: June 21, 2026)
Primary Event: Entry into a Material Definitive Agreement to acquire Arcosa, Inc.
Key Financial Metrics and Transaction Terms
This filing details a merger transaction rather than periodic financial results. Key financial terms include:
- Merger Consideration: $150.00 in cash per share of Arcosa common stock.
- Financing: A $5.75 billion bridge loan facility secured to finance the transaction, refinancing of Arcosa debt, and related fees.
- Termination Fees:
- CRH to pay Arcosa: $371,967,952 (under specific regulatory failure circumstances).
- Arcosa to pay CRH: $260,377,567 (for superior proposals or change of recommendation).
- Debt/Liquidity: The filing does not provide current consolidated debt or liquidity figures for CRH, only the specific bridge loan commitment for this transaction.
Material Changes and Transaction Structure
On June 21, 2026, CRH Americas, Inc. (a subsidiary of CRH) and Arcosa, Inc. entered into a Merger Agreement. Key structural details include:
- Structure: Neon Merger Sub, Inc. will merge with and into Arcosa, with Arcosa surviving as a wholly-owned subsidiary of CRH Americas.
- Equity Treatment: Outstanding Arcosa equity awards will vest and be settled in cash at the merger consideration rate.
- Capital Markets Impact: Upon consummation, Arcosa common stock will be delisted from the NYSE and NYSE Texas.
- Share Buyback: CRH does not expect to initiate a new tranche of its share buyback program following the expiration of the current tranche (ending July 28, 2026).
Guidance, Outlook, Risks, and Contingencies
Closing Conditions: The merger is subject to Arcosa stockholder approval, regulatory approvals (including HSR Act waiting period expiration), and the absence of a material adverse effect.
Timeline: The "Outside Date" for completion is June 21, 2027, with an automatic extension of up to six months if regulatory conditions are pending.
Risks and Contingencies:
- Regulatory Remedial Actions: CRH may be required to divest assets or businesses to obtain antitrust clearance, subject to materiality thresholds.
- Financing: The $5.75 billion bridge loan is expected to be replaced with permanent financing (term loans or senior notes) prior to closing.
- Forward-Looking Statements: Risks include failure to obtain approvals, disruption of operations, litigation, and inability to realize anticipated benefits.
Investor Verification Checklist
- Verify the final approval status of the merger by Arcosa stockholders.
- Monitor regulatory clearance progress, specifically regarding the HSR Act and required divestitures.
- Confirm the terms of the permanent financing intended to replace the $5.75 billion bridge loan.
- Review the definitive proxy statement for detailed financial projections and synergy estimates not included in this 8-K.
- Assess the impact of the suspended share buyback program on CRH's capital allocation strategy.